Want to see ACXP full AI Analyst Report?
ACXP Stock Chart & Stats
$1.42
$0.01(0.70%)
At close: 4:00 PM EDT
$1.42
$0.01(0.70%)
Day’s Range― - ―
52-Week Range$1.31 - $8.34
Previous CloseN/A
Volume25.68K
Average Volume (3M)1.14M
Market Cap
$7.64M
Enterprise Value-$4.05
Total Cash (Recent Filing)$10.66M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.35
Next Earnings
Nov 18, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.55
Shares Outstanding5,269,921
10 Day Avg. Volume3,231,033
30 Day Avg. Volume1,135,368
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.71
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$20.50Price Target Upside1343.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.62
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Pathway ProgressFDA engagement may clarify a potentially streamlined registration pathway for ibezapolstat. Acceptance of PATHFINDER as supportive evidence could improve development efficiency, although approval still depends on robust and consistent results.
Funded Clinical ExecutionA funded trial with imminent enrollment provides a tangible catalyst for generating recurrent-CDI data without immediately requiring financing for this study. Manufacturing readiness also reduces operational barriers to advancing the program.
Defensible Intellectual PropertyBroad geographic patent coverage and additional use protection can strengthen ibezapolstat’s commercial defensibility if clinical development succeeds. The Syfbezi trademark allowance and regulatory designations further support product positioning.
Bears Say
Pre-revenue Operating ModelThe absence of revenue means ACXP has no operating cash engine or commercial validation to fund development. Continued losses leave results dependent on clinical success and external capital, limiting financial durability over the medium term.
Cash Burn And Limited RunwayPersistent cash consumption and highly volatile reported outflows weaken balance-sheet durability despite no debt. The stated roughly one-year runway provides limited time to secure capital before larger development commitments become necessary.
Phase III Funding And Dilution RiskThe pivotal ASPIRE trial cannot advance on current resources alone, creating financing and execution dependence. Equity offerings and warrants can provide capital but may materially dilute existing holders before commercial revenues exist.
Acurx Pharmaceuticals News
ACXP FAQ
What was Acurx Pharmaceuticals’s price range in the past 12 months?
Acurx Pharmaceuticals lowest stock price was $1.31 and its highest was $8.34 in the past 12 months.
What is Acurx Pharmaceuticals’s market cap?
Acurx Pharmaceuticals’s market cap is $7.64M.
When is Acurx Pharmaceuticals’s upcoming earnings report date?
Acurx Pharmaceuticals’s upcoming earnings report date is Nov 18, 2026 which is in 88 days.
How were Acurx Pharmaceuticals’s earnings last quarter?
Acurx Pharmaceuticals released its earnings results on Aug 14, 2026. The company reported -$0.53 earnings per share for the quarter, missing the consensus estimate of -$0.377 by -$0.153.
Is Acurx Pharmaceuticals overvalued?
According to Wall Street analysts Acurx Pharmaceuticals’s price is currently Undervalued.
Does Acurx Pharmaceuticals pay dividends?
Acurx Pharmaceuticals does not currently pay dividends.
What is Acurx Pharmaceuticals’s EPS estimate?
Acurx Pharmaceuticals’s EPS estimate is -0.38.
How many shares outstanding does Acurx Pharmaceuticals have?
Acurx Pharmaceuticals has 5,269,921 shares outstanding.
What happened to Acurx Pharmaceuticals’s price movement after its last earnings report?
Acurx Pharmaceuticals reported an EPS of -$0.53 in its last earnings report, missing expectations of -$0.377. Following the earnings report the stock price went down -5.743%.
Which hedge fund is a major shareholder of Acurx Pharmaceuticals?
Currently, no hedge funds are holding shares in ACXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
ACXP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful regulatory, scientific and IP progress (FDA engagement on a potential single pivotal Phase III pathway, trademark allowance for Syfbezi, fully funded PATHFINDER, manufacturing readiness, partnerships, and strengthened cash vs year-end) while also highlighting material challenges: the need to secure substantial funding to run a large international Phase III (ASPIRE), a limited stated runway (~1 year), rising R&D costs tied to trial startup, ongoing operating losses, and potential dilution from financings. On balance the call emphasized significant program and regulatory momentum but also clear near-term financing and execution risks.View all ACXP earnings summariesACXP Stock 12 Month Forecast
Average Price Target
$20.50
▲(1343.66% Upside)
Technical Analysis
Soligenix
―
GeoVax Labs
―
Cocrystal Pharma
―
Citius Pharmaceuticals
―
Aligos Therapeutics
―
Ownership Overview
45.19%
Insiders
0.87% Mutual Funds
0.26% Other Institutional Investors
53.09% Public Companies and
Individual Investors